LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lineage, Inc. ("Lineage" or the "Company") (NASDAQ: LINE) common stock pursuant and/or traceable to the registration statement used in connection with the Company's July 2024 initial public offering (the "IPO"). IF YOU SUFFERED A LOSS ON YOUR LINEAGE INVESTM ...

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for alleged violations of securities laws, specifically related to misleading statements made by the company regarding its business practices in Medicare services [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that SelectQuote made false and misleading statements to the market, particularly regarding its practices of directing Medicare beneficiaries to plans that provided the highest payments to the company, rather than considering the suitability of those plans for customers [4]. - The class period for the lawsuit is defined as from September 9, 2020, to May 1, 2025, during which investors who purchased the company's securities may have suffered losses [2]. Group 2: Investor Participation - Investors who believe they have incurred losses due to SelectQuote's actions are encouraged to contact the Schall Law Firm before October 10, 2025, to discuss their rights and potentially participate in the class action [2][3]. - The class has not yet been certified, meaning that until certification occurs, affected investors are not represented by an attorney [3]. Group 3: Allegations Against the Company - The complaint alleges that SelectQuote received kickbacks for steering Medicare customers to specific insurers while limiting enrollment options for competitors, which contributed to the misleading nature of the company's public statements [4]. - The misleading statements resulted in significant damages to investors once the truth about SelectQuote's practices became public [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of CTO Realty Growth, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's financial disclosures and practices [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to CTO Realty Growth, Inc. securities purchased between February 18, 2021, and June 24, 2025 [1]. - Allegations include that CTO Realty Growth made false and misleading statements regarding the sustainability of its dividends and the profitability of its Ashford Lane property, leading to an overstatement of its business and financial prospects [5]. Group 2: Investor Participation - Investors who purchased CTO Realty securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by The J.M. Smucker Company and its officers/directors, following disappointing financial results and significant impairment charges related to the acquisition of Hostess Brands [1][3]. Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3]. - For Q3 2025, Smucker reported a comparable net sales decrease of 8% in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [3]. - In Q4 2025, the company experienced a further 14% decrease in comparable net sales in the Sweet Baked Snacks segment, with an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [3]. - Following these announcements, Smucker's stock price dropped by $17.44 per share, or 15.59%, closing at $94.41 per share on June 10, 2025 [3]. Strategic Outlook - The company has revised its 2026 financial plan, indicating decreased net sales in the Sweet Baked Snacks segment due to sustained underperformance since the acquisition, contradicting earlier assurances of synergies driving growth [3].

Core Viewpoint - Albany International Corp. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q2 2025, which led to a significant drop in stock price [1][3]. Financial Performance - Albany reported non-GAAP earnings per share of $0.57 for Q2 2025, missing consensus estimates by $0.16 [3]. - The company's President and CEO acknowledged that the financial results "lagged our expectations" due to "certain timing and operational issues" [3]. - Following the earnings announcement, Albany's stock price fell by $16.77 per share, or 23.63%, closing at $54.19 on July 31, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Albany investors regarding possible securities fraud or other unlawful business practices by the company and its officers/directors [1].

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Centene Corporation (NYSE: CNC) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Centene, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/centene-corporation-class-action-lawsuit. Investors have until September 8, 2025, to ask the ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during the relevant period [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Lineage, Inc. regarding its July 2024 IPO, alleging that the registration statement was misleading and failed to disclose significant operational challenges faced by the company [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Lineage was experiencing a decline in customer demand due to increased cold-storage supply and destocking of excess inventory from the COVID-19 pandemic [5]. - It is alleged that Lineage implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [5]. - The company reportedly failed to counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or declining revenue, occupancy rates, and rent prices [5]. Group 2: Investor Information - Investors who purchased Lineage securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must file by September 30, 2025 [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Spectrum Pharmaceuticals common stock during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its clinical trial [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022 [1]. - The lawsuit claims that Spectrum made false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib intended for lung cancer treatment [5]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][5]. - The lead plaintiff process has been reopened, and interested parties must move the Court by September 24, 2025, to serve as lead plaintiff [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Summit Therapeutics Inc. for alleged violations of securities laws related to misleading statements about its drug study results [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased securities between March 17, 2022, and September 22, 2022, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Summit Therapeutics made false and misleading statements regarding the results of its Pinnacle Study of poziotinib, a treatment for lung cancer [4]. - The misleading public statements caused investors to suffer damages once the truth about the company's situation was revealed [4].